drugset / Trial / NCT05811793
Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.
NaSingle-groupOpen-labelTreatment
Summary
To investigate the efficacy, safety and tolerability of superselective cerebral arterial infusion of Bevacizumab combined with intrathecal injection of Tislelizumab in the treatment of recurrent glioblastoma
Timeline
- Start
- 2023-04-15
- Primary completion
- 2024-12
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Other |
| Subject | Tislelizumab | Monoclonal antibody | 20 mg | Other |